We’ve been asking the same questions for years now, but now we know the answers to them.
The cost of a generic drug has increased significantly over the past decade, and many doctors are reluctant to prescribe them for fear of losing their licenses.
The cost of the next drug will likely be much higher, because the new generic version has to compete with a different, more expensive version.
We spoke with a dozen doctors and pharmacists to find out how the industry is responding to this new reality.
We also got to know the people who make the drug, and the doctors who treat them.
We know that drug costs can vary greatly depending on where you are in the country.
We have a generic version of this painkiller called Ranbaxy.
It’s made by Pfizer, and it costs $100 a tablet.
If you’re in Florida, you can get it for $70.
If your doctor gives you Ranbaxy, you’ll get $140 a tablet, but if you’re not, you’re stuck with $150.
But if you get Ranbasty, you get a $50 discount.
But we’re not talking about a big discount.
If I buy it in a pharmacy, I can get $80 off.
It can be a $20 discount, or a $40 discount.
We’re talking $70, $100, $150, which is about half of what you would get in a Walgreens pharmacy.
That’s a big difference.
And if you look at the prices that are going up on generic versions of the same medicine, you are paying a lot more than $150 for a generic medicine.
So what you’re going to get is a different drug that you have to pay more money for, which could make it more expensive, or make it less expensive.
The prices of generic versions have risen dramatically.
A generic version that costs $50 a tablet in a major pharmacy can cost $150 or more.
The price of a new drug will vary by state.
Some states, like Florida, will pay much less than the generic version, and in others, like California, it could be significantly higher.
So how does it work?
Pharmaceutical companies have a lot of incentives to push out generic versions.
They’ll often pay off the manufacturers who make those generic versions, and they’ll often get big discounts on the brand-name versions, too.
And some drug companies will pay for research and development for the new versions, as well.
But what happens when the generic versions aren’t working out?
We’ve found that it’s not just the generic makers that are the ones pushing out new versions.
It is also a huge chunk of the pharmaceutical industry.
In the early 1990s, the generic drug companies made about a billion dollars a year from generic versions and rebates.
The companies that made the brand name versions, like Pfizer and Johnson & Johnson, made $100 billion a year off of generic drug sales.
The drugs that were the generic ones were cheaper than the brand names.
But by 2008, those rebates were no longer enough.
As the generic companies started losing market share to brand-names, generic rebates had to come in.
And those rebats are still huge for brand-named versions of a drug.
But the big pharmaceutical companies still make money from the generic drugs.
They can get up to $1 billion a month from generic rebate sales.
But the rebates are only $1.5 billion a day, which means that Pfizer makes around $150 billion a week from generic sales.
And Johnson &s; Johnson makes about $2.5 trillion a year.
So the drug companies are not just making money off the rebate, they’re making money from brand-labeled versions.
And so, that’s where the problem comes in.
Because Pfizer made so much money off of rebates, and Johnson& Jans made so little money off brand-specific versions, Pfizer got into a lot worse shape than Johnson &ams.
But Pfizer still makes money from generic drugs, and so does Johnson &.amp; Johnsons.
And that’s a problem for the generic manufacturers.
So Pfizer is paying big rebates to the generic manufacturer to try to keep those rebate prices down.
The generic manufacturer, meanwhile, gets paid a small amount, which it can then sell to Pfizer.
The drug companies aren’t just paying big prices for rebates; they’re also paying big discounts to drugmakers.
If Pfizer gets a rebate, Pfizers rebates go up.
But so does the generic rebat, and Pfizer then gets to keep the rebate price.
The generic manufacturers are also paying drug companies for research, and that’s another big part of the problem.
The pharmaceutical companies want to know more about the brand and what the brand is doing, and if it’s working, they want to make it better.
The rebates aren